CR
Christopher Raymond Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Ardelyx
ARDX
$1.58B
| $6.57 | $9 |
37%
upside
| Neutral | 29 days ago |
|
|
ABVX
2
Abivax
ABVX
$6.47B
| $85.55 | $70 |
18%
downside
| Overweight | 1 month ago |
|
3
Biogen
BIIB
$20.5B
| $139.94 | $115 |
18%
downside
| Neutral | 4 months ago |
|
4
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $126 |
122%
upside
| Overweight | 6 months ago |
|
5
Vertex Pharmaceuticals
VRTX
$102B
| $396.93 | $533 |
34%
upside
| Overweight | 7 months ago |
|
6
Regeneron Pharmaceuticals
REGN
$60.1B
| $567.22 | $1,013 |
79%
upside
| Overweight | 7 months ago |
|
7
Ultragenyx Pharmaceutical
RARE
$3.01B
| $31.28 | $140 |
348%
upside
| Overweight | 7 months ago |
|
8
AbbVie
ABBV
$376B
| $213 | $220 |
3%
upside
| Overweight | 8 months ago |
|
9
Biohaven
BHVN
$1.7B
| $16.07 | $76 |
373%
upside
| Overweight | 11 months ago |
|
10
Tyra Biosciences
TYRA
$647M
| $12.14 | $33 |
172%
upside
| Overweight | 1 year ago |
|
11
Taysha Gene Therapies
TSHA
$889M
| $3.26 | $7 |
115%
upside
| Overweight | 1 year ago |
|
12
Cogent Biosciences
COGT
$1.81B
| $12.94 | $22 |
70%
upside
| Overweight | 2 years ago |
|
13
Akebia Therapeutics
AKBA
$801M
| $3.02 | $4 |
32%
upside
| Overweight | 2 years ago |
|
14
MeiraGTx Holdings
MGTX
$621M
| $7.72 | $25 |
224%
upside
| Overweight | 2 years ago |
|
15
Amgen
AMGN
$151B
| $280.10 | $288 |
3%
upside
| Overweight | 2 years ago |
|
16
Agios Pharmaceuticals
AGIO
$2.1B
| $36.13 | $41 |
13%
upside
| Overweight | 2 years ago |
|
17
On Holding
ONON
$15B
| $46.05 | $28 |
39%
downside
| Overweight | 3 years ago |
|
18
Nuvalent
NUVL
$5.74B
| $79.67 | $40 |
50%
downside
| Overweight | 4 years ago |
|
19
Solid Biosciences
SLDB
$433M
| $5.56 | $90 |
1,519%
upside
| Neutral | 4 years ago |
|